Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A signed informed consent form (ICF);~2. Male or female, at least 18 years of age;~3. Diagnosis requires hospitalization and treatment with intravenous (IV) antibiotics;~4. Documented or suspected cUTI or AP including at least 2 protocol defined signs and symptoms and a urine specimen with evidence of pyuria plus at least one protocol defined associated risk~5. Pretreatment baseline urine culture specimen~6. Expectation that any implanted urinary instrumentation will be removed or replaced not longer than 24 hours, after randomization;~7. Expectation that patient will survive anticipated duration of the study;~8. Patient requires initial hospitalization to manage the cUTI or AP;~9. Women of childbearing potential have had a negative pregnancy test before randomization and be willing to consistently use a highly effective method of contraception~10. Male study participants will be required to use condoms with a spermicide throughout study~Exclusion Criteria:~1. Presence of any of the following conditions: perinephric abscess, renal corticomedullary abscess, uncomplicated urinary tract infection, recent history of trauma to the pelvis or urinary tract, polycystic kidney disease, chronic vesicoureteral reflux, previous or planned renal transplantation; patients receiving dialysis/hemodialysis/CVVH, previous or planned cystectomy or ileal loop surgery; known or suspected infection; caused by pathogen resistant to study treatment antibiotics~2. Presence of suspected or confirmed acute bacterial prostatitis, orchitis, epididymitis, or chronic bacterial prostatitis as determined by history and/or physical examination;~3. Gross hematuria requiring intervention;~4. Urinary tract surgery within 7 days prior to randomization or urinary tract surgery planned during the study period;~5. Creatinine clearance \<20 mL/min using the Cockcroft-Gault formula;~6. Non-renal source of infection such as endocarditis, osteomyelitis, abscess, meningitis, or pneumonia diagnosed within 7 days prior to randomization;~7. Signs of severe sepsis as defined per protocol;~8. Pregnant or breastfeeding women;~9. Known seizure disorder requiring current treatment with anti-seizure medication which would prohibit the patient from complying with the protocol;~10. Cancer chemotherapy, immunosuppressive medications for transplantation, or medications for rejection of transplantation with 30 days of randomization;~11. Significant hepatic disease or dysfunction, including known acute viral hepatitis or hepatic encephalopathy;~12. ALT/AST \>5 × ULN or total bilirubin \>3 × ULN at Screening;~13. Receipt of any potentially-effective systemic antibiotic with activity against Gram-negative uropathogens for more than 24 hours within the 72-hour window prior to randomization (exceptions defined in protocol);~14. Requirement for additional systemic antibiotic therapy (other than study drug) or antifungal therapy for vaginal candidiasis;~15. Likely to require the use of an antibiotic for cUTI or AP prophylaxis during the study;~16. Known history of HIV virus infection and known recent CD4 count \<200/mm3;~17. Presence of significant immunodeficiency or an immunocompromised condition and long-term use of systemic corticosteroids;~18. Presence of neutropenia;~19. Presence of thrombocytopenia;~20. A QT interval corrected using Fridericia's formula \>480 msec;~21. History of significant hypersensitivity or allergic reaction to fosfomycin, any contraindication to the use of piperacillin/tazobactam;~22. Participation in a clinical study involving investigational medication or investigational device within the last 30 days prior to randomization;~23. Inability, in the judgment of the Investigator, to tolerate the salt load required for study drug administration;~24. Unable or unwilling, in the judgment of the Investigator, to comply with the protocol;~25. Any patients previously randomized in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ZTI-01 (Type: EXPERIMENTAL): 6 g ZTI-01 (IV fosfomycin) intravenously administered every 8 hours (18g total daily dose for 7-14 calendar days)
- piperacillin tazobactam (Type: ACTIVE_COMPARATOR): 4.5 g piperacillin/tazobactam (4 g piperacillin/0.5 g tazobactam) intravenously administered every 8 hours (13.5g total daily dose for 7-14 calendar days)

Based on this trial design, predict the completion outcome and termination type (if applicable).